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ABSTRACT
In recent years, several reports have underlined the increasing role of fungal infections as a cause of
morbidity and mortality in hospitalised patients. For this reason, and also in light of the high mortality
rate associated with these infections, chemoprophylaxis has been advocated by several authors. The
available evidence suggests that both ﬂuconazole and itraconazole are able to decrease candida
colonisation and infection, when compared with placebo or with nonabsorbable antifungals. Data seem
also to suggest that a decrease in fungus-related mortality can be achieved with prophylaxis, although
with little effect on overall mortality, probably because of the importance of severe underlying diseases.
Itraconazole proved to be effective in the prevention of fungal infections, including invasive
aspergillosis, although with increased incidence of side-effects, often leading to treatment discontin-
uation. The other side of the coin is that antifungal prophylaxis might have untoward effects, such as the
selection of triazole-resistant Candida strains or the induction of resistance. In addition, some authors
have suggested that the use of triazoles might modulate the pattern of infecting organisms in cancer
patients, increasing the risk of both aspergillosis and bacteremia. In conclusion, antifungal prophylaxis
with triazole antifungals should be used with caution, only in patients at high risk for invasive fungal
infections. These include allogeneic bone marrow transplant patients (especially those with mismatched
or unrelated donors), acute myeloid leukaemia patients treated with high-dose cytarabine (C-ara), very-
low-birth-weight infants, patients with chronic granulomatous disease, and high-risk surgical and
intensive-care unit patients.
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BACKGROUND
In recent years, several reports have underlined
the increasing role of fungal infections as a cause
of morbidity and mortality in hospitalised
patients. For example, a national survey of
nosocomial fungal infections in American hospi-
tals (Hospital Infection Program, Centers for
Disease Control, Atlanta, GA) showed that the
incidence of these infections increased from 2.0
to 3.8 infections ⁄ 1000 discharges from 1980 to
1990, with the incidence of nosocomial candide-
mia increasing from 1.0 to 4.9 infections ⁄ 1000
discharges [1]. There are studies (including
autopsy studies) performed on both sides of
the Atlantic Ocean showing a well-documented
increase in fungal infections in cancer patients
[2,3], especially in leukaemic patients and in
those undergoing bone marrow or stem cell
transplantation [4]. In American hospitals, Can-
dida now represents the fourth most frequent
pathogen isolated in blood culture [5]. The
incidence of fungal infections varies according
to the underlying condition and is higher in
burn ⁄ trauma intensive-care units [6]. Patients
undergoing major abdominal surgery are also
at risk for fungal infection, with an incidence
approaching 40% [7]. The frequency of fungal
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infection in solid organ transplant recipients has
been recently reviewed by Singh et al. [8]. They
found a decreasing incidence of invasive can-
didiasis, and an increasing incidence of invasive
aspergillosis over the last 10 years. In intensive-
care units, epidemiological data concerning inci-
dence and prevalence are much less clear,
because of some confusion between colonisation
and infection. For example, in a classic preval-
ence study performed on 21 April 1992, Vincent
et al. found that 24% of the patients were
infected and that fungi accounted for 17% of
the isolated pathogens [9]. More recently, how-
ever, Blumberg et al. reviewed 4276 admissions
in intensive-care units in America and found that
candidemia was observed in 1% of the patients
[10]. Very-low-birth-weight infants admitted to
intensive-care units are also at high risk for
developing fungal infections [11].
There are indications that the pattern of infect-
ing fungal organisms is changing. Among fungal
pathogens, moulds are certainly increasing more
than yeasts. For example, Groll et al., in a large
autopsy study, clearly showed that the overall
increase in fungal infection was mainly the result
of an increase in infections by ﬁlamentous fungi,
including species that were never known to be a
cause of human infections in the past [3]. Among
yeasts, for years, Candida albicans was the most
frequently isolated species among candida iso-
lates. Recently, a surveillance study of fungemia
in cancer patients conducted by the Invasive
Fungal Infection Group of the EORTC revealed
that non-albicans Candida had become prevalent
among patients with leukaemia and lymphoma
[12]. This phenomenon seems to be common to
almost all compromised patients, although its
proportions in other patient populations may not
be as evident as in cancer patients [13]. Although
fungal infections usually do not represent more
than 10% of all infections, the mortality they
cause remains very high. There is general agree-
ment that from 80% to 95% of patients with
cerebral aspergillosis die from the disease [14],
while the mortality rate from candidemia may
vary from 25% to 50%, according to the under-
lying condition [12].
In the light of the high mortality rate, prevent-
ing invasive fungal infections has always been
considered a desirable approach. Unfortunately,
until about a decade ago, the antifungal arm-
amentarium was very limited. Both the polyenes
and the azoles available at that time were not
absorbed by the oral route and their use was
limited to intestinal decontamination. Intravenous
administration was not practical and was associ-
ated with important toxicity. When the triazole
became available, several investigators started
clinical trials to examine the effects of these drugs
for prophylactic purposes.
In the following text we will summarise
advantages and disadvantages related to the use
of antifungal prophylaxis in patients at risk for
fungal infections, excluding patients infected with
human immunodeﬁciency virus (HIV). Because
ﬂuconazole and itraconazole, the two triazole
drugs that have been extensively used in prophy-
laxis, have a different spectrum of action and
different pharmacological properties, we will deal
with them separately. The purpose of this article
will be not only to review the most important
studies performed in this ﬁeld but also to put
their results in perspective compared to other
studies that showed or suggested the possibility
that prophylaxis might also carry some untoward,
undesirable effect.
FLUCONAZOLE
According to Bow et al., 69 trials of antifungal
prophylaxis in cancer patients were found in a
literature search from 1966 to 2000 [15]. Among
them, 38 were comparative trials, having placebo,
no treatment or a polyene as control regimen, and
were therefore evaluable for the purpose of the
analysis. Most of the trials (17 of 38 or 58% of
patients in randomised trials) included ﬂuconaz-
ole as study regimen. Eight ﬂuconazole studies
included at least 100 patients per arm. With the
exception of the very early studies, ﬂuconazole
was almost always given at the relatively high
dose of 400 mg ⁄day or 3–15 mg ⁄kg ⁄day. The ﬁrst
randomised, double-blind placebo-controlled
study was published by Goodman et al. in 1992
[16]. In a population of patients undergoing
autologous and allogeneic bone marrow trans-
plantation (BMT), a statistically signiﬁcant
advantage of ﬂuconazole was shown in the
reduction of invasive candidiasis. In this study,
ﬂuconazole was given from the day of initiation
of the transplant-conditioning regimen to engraft-
ment. Shortly after, Slavin et al. published another
large study in a slightly different patient popula-
tion, including only recipients of allogeneic grafts.
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The administration of the study drugs was not
discontinued at engraftment but was continued
until day 75 after transplant, to cover the acute
graft-versus-host disease period. In this study the
administration of ﬂuconazole was associated not
only with a reduction of invasive candidiasis, but
also with improved survival [17]. Very interest-
ingly, the same group performed an 8-year
follow-up of the patients randomised in the
Slavin study. The results of the long-term fol-
low-up were surprising because a statistically
signiﬁcant survival advantage was still present
among patients who 8 years before had been
randomised in the ﬂuconazole arm, with a reduc-
tion in the overall number of invasive candidiasis
and candidiasis-related deaths as well as severe
intestinal graft-versus-host disease [18]. From the
same group, another conﬁrmation of the positive
effects of ﬂuconazole prophylaxis in allogeneic
BMT came from a study on the effect of BMT from
unrelated donors in patients with chronic mye-
loid leukaemia. In these patients, administration
of ﬂuconazole was signiﬁcantly associated with
improved survival [19].
In patients with acute leukaemia, the positive
effects of ﬂuconazole prophylaxis were less
impressive. Winston et al. failed to demonstrate a
signiﬁcant advantage of ﬂuconazole in preventing
invasive infections or reducing mortality [20].
Menichetti et al., who published the largest clinical
trial of ﬂuconazole vs. a nonabsorbable antifungal
drug in acute leukaemia patients, did not show
any difference between ﬂuconazole and oral
amphotericin B. In this study, ﬂuconazole was
given at the relatively low dose of 150 mg daily
[21]. In a placebo-controlled study in adults with
acute leukaemia [22], Rotstein et al. showed that
ﬂuconazole at a dose of 400 mg ⁄day reduced the
incidence of probable or documented invasive
fungal infections, especially among patients with
acute myelogenous leukaemia receiving remis-
sion-induction chemotherapy with cytarabine
plus anthracycline regimens (administerd for 7
and 3 days, respectively) and high-dose cytara-
bine-containing regimens. Finally, in a very recent
study ﬂuconazole at 200 mg ⁄day was compared
with low-dose amphotericin B (0.2 mg ⁄kg ⁄day) in
186 haematopoietic stem cell transplant recipients
[23]. No difference was observed in terms of
study discontinuation for persistent fever, proven,
suspected, or superﬁcial fungal infections, or
survival at day 100 after transplant.
Fluconazole has been administered as antifun-
gal prophylaxis in other compromised patients. A
placebo-controlled study performed by Eggiman
et al. [24], in a very select group of high-risk
surgical patients (those undergoing a second
laparatomy), showed that the administration of
400 mg of ﬂuconazole signiﬁcantly reduced the
incidence of invasive candidiasis. Similar results
were obtained by Pelz et al. in critically ill surgical
patients, staying in the intensive-care unit longer
than 3 days [25], and by Garbino et al., who
showed an advantage of low-dose ﬂuconazole
(100 mg daily) in reducing Candida colonisation
and candidemias, with no effect on either invasive
candidiasis or overall mortality [26].
Very-low-birth-weight infants represent an-
other group of patients at risk for severe Candida
infection [11]. In a recent randomised double-blind
placebo-controlled study, ﬂuconazole adminis-
tered at 3 mg ⁄ kg and administered according to
an age-adapted schedule, reduced both fungal
colonisation and invasive fungal infections in
neonates weighing less than 1000 g, requiring a
vascular access or endotracheal intubation [27].
Fluconazole could not be expected to be effect-
ive against ﬁlamentous fungi, such as Aspergillus,
which represent an important cause of morbidity
and mortality, especially in patients with acute
leukaemia and in those undergoing BMT. Indeed,
no study showed any advantage for ﬂuconazole
in the prevention of invasive aspergillosis,
although the incidence of these infections was
seldom reported.
ITRACONAZOLE
With respect to ﬂuconazole, itraconazole posses-
ses a broader spectrum of action, which includes
some Candida strains that are intrinsically resist-
ant to ﬂuconazole (C. kruzei) and Aspergillus.
According to Bow et al. [15], ﬁve randomised
trials are available in which itraconazole was
compared with placebo or polyenes. Of them,
four studies included at least 100 patients per arm
[28–31]. In a double-blind placebo-controlled
study performed by the GIMEMA (Gruppo Italia-
no Malattie Ematologiche dell’Adulto) with 405
neutropenic patients [28] itraconazole oral solution
administered at 5 mg ⁄ kg ⁄day resulted in effective
reduction of the incidence of candida infections in
leukaemic adults. Unfortunately, no effect was
shown on the incidence of invasive aspergillosis.
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In a similar trial with 557 patients, comparing
itraconazole oral solution with placebo [29], the
incidence of proven systemic fungal infections, the
number of deaths due to invasive mycoses and the
use of empiric antifungal therapy seemed to be
lower in the itraconazole group, but no statistically
signiﬁcant difference could be documented. In
another double-blind placebo-controlled study in
210 patients with haematological malignancies or
receiving autologous BMT [30] itraconazole cap-
sules administered at 100 mg twice daily showed a
redution in the use of empiric antifungal therapy
and a reduced incidence of fungal infection in the
subgroup of patients with severe (< 100 ⁄mm3) and
prolonged (> 7 days) neutropenia. Finally, a trend
in the reduction of deep fungal infections, especi-
ally in patients with severe (< 100 ⁄mm3) and
prolonged (> 2 weeks) neutropenia, was docu-
mented in a trial comparing itraconazole oral
solution with amphotericin B plus nystatin in 277
patients [31]. Unfortunately, no signiﬁcant differ-
ence in major end points, such as incidence of
invasive mycoses or mortality, could be detected.
In contrast, in a recent meta-analysis Glasmach-
er and colleagues [32] studied the pooled effect of
itraconazole prophylaxis on several markers of
efﬁcacy, including the incidence of aspergillosis.
They included all kinds of itraconazole studies,
and not only placebo or no-treatment-controlled
studies. Itraconazole (any formulation) signiﬁ-
cantly reduced the incidence of invasive fungal
infection, invasive yeast infections, and fungal-
associated mortality. The incidence of invasive
aspergillosis was only reduced when the oral
solution was used, with a clear dose-dependent
(and concentration-dependent) effect, and at the
price of a higher incidence of drug-related adverse
events and drug discontinuations.
Itraconazole has also been tested in patients
with rare diseases, such as chronic granulomatous
disease. In a prospective, open-label study with 30
patients, administration of itraconazole reduced
the incidence of pulmonary aspergillosis from
11.5 ⁄ 100 patients-year, observed in historical con-
trols not receiving prophylaxis, to 3.4 in subjects
treated with 5 and then 10 mg ⁄ kg ⁄day of itracon-
azole [33]. Despite the severity of invasive fungal
infections in chronic granulomatous disease pa-
tients and the availability of convincing data in
favour of prophylaxis, a randomised, double-
blind and placebo-controlled clinical trial was
deemed necessary [34]. In this controversial trial,
which enrolled 39 patients, there were seven
serious fungal infections in placebo recipients
compared with only one in itraconazole recipients.
EFFECTS OF ANTIFUNGAL
PROPHYLAXIS IN METANALYSES
At least three large metanalyses of the effects of
antifungal prophylaxis in cancer patients have
been published [15,35,36]. The control areas in
these studies were placebo, no treatment or a non-
absorbable polyene. The Cochrane study [34] was
clearly biased by the inclusion of both antifungal
prophylaxis and empiric therapy, showing that
clinical expertise should always support the
statistical work. The study by Kanda et al. [36]
showed positive effects of prophylaxis only in
studies in which the incidence of systemic fungal
infections was higher than 15%. Finally, the study
by Bow and colleagues reviewed 38 randomised,
controlled studies including more than 7000
patients. The study found that the use of antifun-
gal prophylaxis, mostly with azole drugs (94% of
the patients), was associated with a reduction in
the use of parenteral antifungal therapy, in the
occurrence of both superﬁcial and invasive fungal
infections and in fungal-related mortality, with a
pooled-weighted odds ratio of 0.59 (0.50–0.67). In
the subpopulations of patients with prolonged
neutropenia and in recipients of allogeneic BMT
there was also a reduction in the overall mortality.
Another metanalysis of the effect of ﬂuconazole
prophylaxis in very-low-birth-weight infants was
performed by the Cochrane group, with the aim
of assessing whether intravenous prophylactic
antifungal drugs reduced mortality and adverse
neurodevelopmental outcomes [37]. Among the
203 patients enrolled into studies comparing
ﬂuconazole with placebo, infants who received
ﬂuconazole prophylaxis had a reduced risk of
death prior to hospital discharge, suggesting
efﬁcacy of ﬂuconazole prophylaxis in these
patients, even if no data about long-term outcome
was available.
FLUCONAZOLE VS. ITRACONAZOLE
In acute leukaemia and BMT patients Huijgens
et al. found no difference in the incidence of
fungal infections in the two arms of the study [38],
while another study reported a slight, but not
statistically signiﬁcant, advantage for itraconazole
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[39]. In an open-label study, Winston et al. com-
pared intravenous and oral ﬂuconazole with
intravenous and oral itraconazole in BMT patients
[40]. Both drugs were given for 100 days after
transplant. Itraconazole performed better than
ﬂuconazole, with an incidence of invasive fungal
infections of 9% vs. 25%. However, also in this
context, there were relatively fewer cases of
invasive aspergillosis (three in the itraconazole
group vs. eight in the ﬂuconazole group).
Finally, Marr and colleagues [41] compared
itraconazole vs. ﬂuconazole in the prophylaxis of
infection in BMT patients. In this study the dose
of itraconazole was adjusted to maintain serum
levels to at least 0.5 lg ⁄mL. This was obtained
with a dose of 2.5 mg ⁄kg two or three times a day.
Among patients able to tolerate this high dosage,
itraconazole effectively prevented fungal infec-
tion, with a signiﬁcant effect on the incidence of
aspergillosis as well. However, almost one-quar-
ter of the patients discontinued itraconazole
because of gastro-intestinal side-effects. In addi-
tion, an important toxic interaction between itr-
aconazole and cyclophosphamide was detected in
this study, leading to the recommendation of not
administering the two drugs concomitantly [42].
In orthotopic liver transplant recipients, a
patient population in which the incidence of
fungal infections is relatively low, Winston et al.
randomised 188 patients to receive either itrac-
onazole or ﬂuconazole. Again, the two drugs
were shown to be equivalent in reducing fungal
colonisation. As expected, no conclusion could be
drawn, because the incidence of fungal infections
was very low in both arms [43]. Finally, it is
worthwhile to report the execution of two pro-
phylactic clinical trials, in which patients were
randomised to receive an unorthodox combina-
tion of antifungal drugs. Biancoﬁore et al. rand-
omised 129 consecutive orthotopic liver
transplant recipients to receive sequential treat-
ment with intravenous liposomal amphotericin B
+ oral itraconazole, intravenous ﬂuconazole + oral
itraconazole, or intravenous and oral placebo [44].
Mattiuzzi et al. randomised 139 patients with
newly diagnosed acute myeloid leukaemia or
myelodysplastic syndrome to receive antifungal
prophylaxis with liposomal amphotericin B or the
association of itraconazole + ﬂuconazole [45]. It is
quite difﬁcult to understand the rationale behind
these choices and how the studies were planned
from a statistical point of view. Needless to say,
both studies showed no statistically signiﬁcant
difference between the study arms.
SECONDARY PROPHYLAXIS
Patients with a history of invasive aspergillosis
(IA) appear to be at high risk for reactivation
when undergoing further chemotherapy. This is
probably because the fungal organisms remain
viable in these lesions. Whether or not the risk of
relapse depends on the persistence of lesions is a
matter of controversy. According to Martino et al.
[46], the risk is lower in the presence of a complete
radiological response, while for Offner et al. [47],
patients may relapse even in the absence of
residual lesions. What everybody agrees upon is
that a history of IA is not an absolute contrain-
dication to further chemotherapy and BMT [48–
51]. Ideally, patients needing further treatment for
leukaemia should undergo surgical excision of
the pulmonary lesions, but this is often impossible
because of the impending risk of leukaemia
relapse or because of the presence of multiple,
bilateral lesions. In any case, even surgical exci-
sion does not guarantee complete cure, because
aspergillosis is usually a multifocal disease, at
least at the microscopic level [52]. Therefore, even
if this indication has never been proved in large-
scale clinical trials, secondary antifungal prophy-
laxis (or pre-emptive therapy) remains the only
possible option for these patients. The drug of
choice seems to be amphotericin B (in any
formulation), but itraconazole (alone or in com-
bination) has also been used [53–55]. Two reports
have suggested that voriconazole might also be a
suitable choice for secondary prophylaxis of




Untoward effects related to the administration of
antibiotics can be classiﬁed as toxic, allergic,
idiosyncratic, related to the antimicrobial activity
of the drug and related to other effects, independ-
ent of the antimicrobial activity. In the particular
case of triazole drugs, toxicity and allergic reac-
tions are of limited importance. Indeed, triazoles
are usually well tolerated, and no severe side-
effect has ever been reported, even when prophy-
laxis is administered for long periods. More
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important are the effects unrelated to the anti-
microbial activity, especially with itraconazole.
Indeed, while ﬂuconazole is poorly metabolised
and is eliminated mainly by the renal route,
itraconazole undergoes extensive metabolization,
with some variability between subjects. Itraconaz-
ole is both a substrate and an inhibitor of the
cytochome P450 enzyme system, and therefore
tends to inhibit its own metabolism with a conse-
quent trend to accumulation. More importantly,
itraconazole may interact with other drugs that are
metabolised through the samemetabolic pathway,
a phenomenon that must be recognised because of
the increased risk of adverse reactions [42,58].
The prolonged and widespread administration
of antifungal prophylaxis with triazoles in patients
at risk for fungal infections has been correlated,
with variable degrees of certainty, with possible
untoward effects related to that very activity of
antimicrobial agents which allows them to modify
the micro-ecology of human beings. Indeed, the
potential for these side-effects, which for obvious
reasons are peculiar to antibiotics, should be
recognised and carefully considered, when dis-




The possible role of antifungal prophylaxis with
azole compounds in increasing the rate of bac-
teremia among febrile and neutropenic patients
was ﬁrst raised by Palmblad et al. in 1992 [59]. In a
small, randomised, double-blind trial of ketocon-
azole vs. placebo, they found that the incidence of
febrile episodes was the same in both groups, but
that the administration of ketoconazole was
apparently affecting the type of fever documen-
tation. Indeed, there were many more bacteremias
among patients receiving ketoconazole than
among those receiving placebo (74% vs. 37%),
while clinically documented infections and unex-
plained fevers were prevalent in the placebo
group. As a result of the small size of the study
(107 patients), there is the possibility that this
difference was chance. However, similar results
were also reported by Shaffner et al. in a slightly
larger study of ﬂuconazole vs. placebo [60]. They
reported a 36% incidence of bacteremia in
ﬂuconazole recipients, compared with 21% in
placebo recipients. More recently, in a large
prospective, randomised clinical trial of itracon-
azole oral solution against placebo, Menichetti
et al. again found a higher rate of bacteremia
among patients receiving prophylaxis [28].
Although the duration of neutropenia was the
same in both groups, the rate of bacteremia was
23% in itraconazole recipients compared with
15% in placebo recipients (P ¼ 0.037). As re-
viewed by Palmblad [61], other authors appar-
ently did not ﬁnd the same effect, although the
incidence of bacteremia was rarely reported in
these studies. In 1994, in a study aimed at
identifying, at the onset of fever during neutrope-
nia, those factors more likely to be associated with
the risk of bacteremia, we also found administra-
tion of antifungal prophylaxis to be an independ-
ent prognostic factor for bacteremia, with an odds
ratio estimate of 2.48 and a conﬁdence interval at
95% ranging from 1.49 to 4.13 on a derivation set
of 558 episodes [62]. Finally, in 2001 we published
a retrospective study based on prospectively
collected data to give further insight into this
problem [63]. Starting from a database of 3002
febrile and neutropenic patients enrolled in four
therapeutic trials performed by the International
Antimicrobial Therapy Group of the EORTC from
1986 to 1994, we found that the rates of bactere-
mia were 20%, 26% and 27% (P ¼ 0.0001) among
patients not receiving antifungal prophylaxis,
receiving nonabsorbable drugs, or receiving triaz-
oles, respectively. In a multivariate model without
including antifungal prophylaxis, factors associ-
ated with bacteremia were age, duration of
hospitalisation, duration of neutropenia before
fever, underlying disease, presence of an intra-
venous line, presence of a site of infection, shock,
antibacterial prophylaxis, temperature and gra-
nulocyte count at onset of fever. When antifungal
prophylaxis was included, the adjustment quality
of the model improved slightly (P ¼ 0.05), with
an odds ratio of 1.19 (95% CI 0.92–1.55) for
patients receiving nonabsorbable drugs and 1.42
(95% CI 1.07–1.88) for those receiving triazoles.
Finally, very recently Cordonnier et al. [64] again
found antifungal prophylaxis to be a factor
independently associated with the risk of strep-
tococcal bacteremia in febrile and neutropenic
patients. In conclusion, although no causal rela-
tionship could be demonstrated and the role of
antifungal prophylaxis on the rate of bacteremia
might well be a marker for other variables not
recorded in our database, the data were at least
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suggested that every clinical trial of antifungal
prophylaxis should record and report the rate of
bacteremia among patients enrolled.
TRIAZOLE PROPHYLAXIS AND
EMERGENCE OF NON-ALBICANS
CANDIDA OR MOULD INFECTIONS
Several reports have focused on the increasing
rate of colonisation and infection by the natively
resistant Candida species (C. krusei and C. glabrata)
in leukaemic or BMT patients receiving ﬂucona-
zole [65–67]. Although this phenomenon was not
conﬁrmed in large prospective studies
[17,20,21,68,69], it would be surprising if antifun-
gal prophylaxis had no effect on the pattern of
pathogens causing infection in patients receiving
prophylaxis. Indeed, in a surveillance study of
candidemia in cancer patients, we found that
administering antifungal prophylaxis, not only
with ﬂuconazole, was one of the factors associated
with an increasing risk of non-albicans candidemia
[12]. The other factors identiﬁed were severity of
the underlying disease and neutropenia.
Prior use of ﬂuconazole has been associatedwith
an increase in the incidence of mould infections,
mainly invasive aspergillosis, both in BMT and
other immunocompromised patients [69,70]. The
explanation of this phenomenon is quite difﬁcult
and could range from a lack of ‘colonisation
resistance’ (as described for bacterial infections)
to a simple reduction of disease andmortality from
candida infection allowing the ‘emergence’ of
Aspergillus. An interesting point of view has been
recently presented [71] with the suggestion that
ﬂuconazole, even if inactive against Aspergillus
strains, could up-regulate the expression of some
genes from these fungi with the consequent tras-
formation of a previous colonisation or locally
invasive infection to a full-blown invasive asper-
gillosis, perhaps refractory to antifungal drugs.
TRIAZOLE PROPHYLAXIS AND
EMERGENCE OF RESISTANCE
In addition to the increased frequency of infec-
tions by naturally ﬂuconazole-resistant Candida
strains (C. krusei and C. albicans), HIV-infected
patients undergoing prolonged treatment with
ﬂuconazole presented infections caused by Can-
dida strains which ‘acquired’ resistance to the new
azoles [72]. Although this has been shown in
other immunocompromised patients [73], the
practical importance of this phenomenon is prob-
ably negligible and the emergence of clinical
problems related to acquired resistance can be
considered anecdotal.
CONCLUSION
There is clear evidence, in our opinion, that every
approach to the prophylaxis of infectious compli-
cations in immunocompromised patients should
be tailored to the individual patient risk, to local
epidemiological factors and to the results of
clinical trials. In this sense, as shown in Table 1,
it is likely that triazole antifungal prophylaxis
directed against the prevention of candida infec-
tions could be recommended in allogeneic BMT
patients (especially those undergoing transplan-
tation from unrelated donors and mismatch
transplants), in acute myeloid leukaemia patients
treated with high-dose cytarabine with or without
anthracyclines, in very-low-birth-weight infants,
in patients with chronic granulomatous disease,
and in high-risk surgical and intensive-care unit
patients. Both itraconazole and ﬂuconazole have
shown activity, although there is some concern
about itraconazole’s toxicity proﬁle and the risk of
drug interactions. Other patient populations that
might deserve prophylaxis include liver and lung
transplant recipients, especially if in high-risk
conditions (re-transplantation, re-interventions,
heavy candida colonisation). The adverse biolo-
gical consequences of an excessive use of antibi-
otics for prophylaxis and treatment, both in the
individual patient and in the environment, are of
the utmost importance, and the consequences are
even more serious when the effectiveness of these
procedures has not been properly demonstrated.
The risk of selecting for natively resistant Candida
strains or moulds, the risk of inducing acquired
resistance and the possible effect on the incidence
of severe bacterial infections play against a wide-
spread use of prophylaxis in other patient categ-
ories.
For reasons that have already been addressed,
antifungal prophylaxis has almost never been
targeted speciﬁcally at the prevention of invasive
aspergillosis. Clinical trials that have evaluated
the impact of prophylaxis on aspergillosis have
failed to show any advantage. This is particularly
disappointing, because nowadays aspergillosis
represents the most important ‘killer’, at least in
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haematological patients. We look forward to new
drugs that will be able to cope with this funda-
mental problem.
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